Amgen 2010 Annual Report Download - page 147
Download and view the complete annual report
Please find page 147 of the 2010 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137 -
138 -
139 -
140 -
141 -
142 -
143 -
144 -
145 -
146 -
147 -
148 -
149 -
150 -
151 -
152 -
153 -
154 -
155 -
156 -
157 -
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
 |
 |
13. Intangible assets
Amortization of finite-lived intangible assets is provided over their estimated useful lives ranging from 5 to
15 years on a straight-line basis (weighted average remaining amortization period of 6 years at December 31, 2010).
Finite-lived intangible assets consisted of the following as of December 31, 2010 and 2009 (in millions):
Intangible assets subject to amortization
Weighted
average
amortization
period 2010 2009
Acquired product technology rights:
Developed product technology ................................ 15years $ 2,872 $ 2,872
Core technology .......................................... 15years 1,348 1,348
Trade name .............................................. 15years 190 190
Acquired R&D technology rights ................................ 5years 350 350
Other intangible assets ....................................... 10years 627 541
5,387 5,301
Less accumulated amortization ................................. (3,157) (2,734)
$ 2,230 $ 2,567
Acquired product technology rights relate to the identifiable intangible assets acquired in connection with the
2002 Immunex acquisition and the amortization is included in “Amortization of certain acquired intangible assets”
in the Consolidated Statements of Income. Intangible assets also include acquired R&D technology rights
consisting of technology used in R&D with alternative future uses and the amortization is included in “Research
and development” expense in the Consolidated Statements of Income. The amortization of other intangible assets is
included principally in “Cost of sales (excludes amortization of certain acquired intangible assets)” and “Selling,
general and administrative” expense in the Consolidated Statements of Income. During the years ended Decem-
ber 31, 2010, 2009 and 2008, we recognized amortization charges associated with our intangible assets of
$423 million, $425 million and $425 million, respectively. The total estimated amortization for each of the next five
years for our intangible assets is $353 million, $331 million, $331 million, $316 million and $309 million in 2011,
2012, 2013, 2014 and 2015, respectively.
14. Accrued liabilities
Accrued liabilities consisted of the following as of December 31, 2010 and 2009 (in millions):
2010 2009
Sales deductions ........................................................ $1,144 $ 970
Employee compensation and benefits ......................................... 764 751
Clinical development costs . . . ............................................. 230 361
Sales returns reserve ..................................................... 339 211
Other ................................................................ 889 1,006
$3,366 $3,299
F-25
AMGEN INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)